The suppression of gastric acid secretion with anti-secretory agents has been the mainstay of medical treatment for patients with acid-related disorders. Although the majority of Helicobacter pylori-related peptic ulcers can be healed with antibiotics, ulcer healing and symptom control can be signi®cantly improved when antibiotics are given with anti-secretory agents, especially with a proton pump inhibitor. There is a dynamic relationship between the suppression of intragastric acidity and the healing of peptic ulcer and erosive oesophagitis and control of acid-related symptoms. The suppression of gastric acid secretion achieved with H 2 -receptor antagonists has, however, proved to be suboptimal for eectively controlling acidrelated disorders, especially for healing erosive oesophagitis and for the relief of re¯ux symptoms. H 2 -receptor antagonists are also not eective in inhibiting meal-stimulated acid secretion, which is required for managing patients with erosive oesophagitis. Furthermore, the rapid development of tolerance to H 2 -receptor antagonists and the rebound acid hypersecretion after the withdrawal of an H 2 -receptor antagonist further limit their clinical use. Although low-dose H 2 -receptor antagonists are currently available as over-the-counter medications for self-controlling acid-related symptoms, their pharmacology and pharmacodynamics have not been well studied, especially in the self-medicating population. Proton pump inhibitors have been proved to be very eective for suppressing intragastric acidity to all known stimuli, although variations exist in the rapidity of onset of action and the potency of acid inhibition after oral administration at the approved therapeutic doses, which may have important clinical implications for the treatment of gastro-oesophageal re¯ux disease and perhaps for eradicating H. pylori infection when a proton pump inhibitor is given with antibiotics. Once-daily dosing in the morning is more eective than dosing in the evening for all proton pump inhibitors with respect to the suppression of intragastric acidity and daytime gastric acid secretion in particular, which may result from a better bio-availability being achieved with the morning dose. When higher doses are needed, these drugs must be given twice daily to achieve the optimal suppression of 24 hour intragastric acidity. Preliminary
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Results from numerous comparative clinical trials and meta-analyses of these studies have shown that PPIs are signi®cantly more eective than H 2 RAs for suppressing gastric acid secretion and healing duodenal and gastric ulcers and erosive oesophagitis, and for the relief of acid-related symptoms. PPIs are also signi®cantly more eective than H 2 RAs or misoprostol for preventing and healing NSAID-associated ulcer disease. 6 This chapter reviews the pharmacological and pharmacodynamic essentials of both H 2 RAs and PPIs and their clinical relevance in the management of acid-related disorders.
H 2 -RECEPTOR ANTAGONISTS
Four H 2 RAs have been used worldwide for more than two decades ± cimetidine, ranitidine, famotidine and nizatidine ± roxatidine also having been marketed in a number of regions. These agents are speci®c antagonists that inhibit acid secretion by competitively and reversibly blocking the H 2 -receptors on the basolateral membrane of the parietal cell. The drugs dier slightly in structure but have many similarities in their pharmacological properties. H 2 RAs only partially inhibit the acid secretion stimulated by gastrin and are more eective for inhibiting intragastric acidity during periods of basal acid secretion. 7, 8 As the longest period of basal acid secretion occurs nocturnally, dosing after an evening meal or at bedtime is optimal for these agents. 9, 10 In an early study comparing dierent dosing regimens of cimetidine (400 mg twice a day or 300 mg at night) and ranitidine (150 mg twice daily or 300 mg at night), Gledhill et al showed no signi®cant dierence between these two dosing regimens for both cimetidine and ranitidine in the reduction of 24 hour intragastric acidity. Nocturnal acid secretion was, however, controlled signi®cantly better with ranitidine at night. 9 Furthermore, recent studies suggest that bedtime ranitidine 150 or 300 mg is more eective than bedtime omeprazole 20 mg for controlling the nocturnal acid breakthrough observed in subjects treated with omeprazole 20 mg twice daily. 11, 12 Acid breakthrough, de®ned as a decrease in intragastric pH to less than 4 for 1 hour or more, occurs nocturnally in more than 90% of subjects receiving omeprazole 20 mg twice daily. 12 This phenomenon is considered to be driven largely by histamine.
11,12
The clinical signi®cance of the nocturnal acid breakthrough is, however, not clear. Although evening dosing regimens provide prolonged nocturnal acid suppression, they are ineective for suciently increasing daytime intragastric pH and cannot overcome food-stimulated acid secretion. 13, 14 Many patients do not respond to H 2 RAs despite increased dosages. 15 Furthermore, H 2 RAs are not eective for suppressing peptic activity and pepsin secretion during the daytime, as shown in many 24 hour pHmonitoring studies. 16±18 The suppression of nocturnal acid secretion achieved with an evening dose of H 2 RAs may therefore be more relevant for managing patients with duodenal ulcer than with GORD, since healing GORD requires the eective control of both daytime and night-time gastric acid secretion.
Numerous controlled clinical trials have been published regarding the eects of H 2 RAs on gastric acid suppression and the relationship between the inhibition of acid secretion and the healing of peptic ulcers and GORD, and these have been systematically analysed by our group. 2±5,19 Nevertheless, several interesting and important issues deserve further discussion, for example the development of tolerance to H 2 RAs, rebound acid hypersecretion and the pharmacodynamics and clinical uses of low-dose H 2 RAs.
Tolerancè
Tolerance' is a term frequently used in clinical pharmacology but often misunderstood and poorly explained in studies examining the eect of H 2 RAs in the treatment of acidrelated disorders. By de®nition,`tolerance' has developed when it becomes necessary to increase the dose of a drug to obtain an eect previously seen with a lower dose. This strict de®nition does not apply to H 2 RAs for several reasons:
1. Increasing the dose of ranitidine does not achieve the same anti-secretory eect in the clinical situation or experimentally when given by a pH feedback pump after chronic oral dosing. 20 2. Clinical experience with H 2 RAs during chronic treatment, for example in the maintenance treatment of duodenal ulcer, does not support progressive pharmacological tolerance since there is no need to increase the dose of H 2 RAs in order to keep patients in remission. 21 Therefore, the change of response to H 2 RAs may be better explained by an exaggerated`®rst-dose' eect, as has been shown with many types of anti-hypertensive drugs. 20 Theoretically, the development of tolerance to H 2 RAs is particularly likely to occur when a high dose is used. This has been con®rmed by several recent studies examining the anti-secretory eect of high-dose ranitidine given orally over varying periods of continuous treatment. 22±26 Lachman and Howden examined the development of pharmacological tolerance to 5 day continuous treatment with ranitidine 150 mg four times a day, a recommended dose for treating patients with GORD. 22 The mean 24 hour intragastric pH increased from 2.62 at pre-dosing to 4.22 on day 1 of ranitidine administration and 3.28 on day 5. There was a signi®cant fall in the mean 24 hour intragastric pH between day 1 and day 5 of ranitidine treatment (P 0.001). Similar dierences were also observed in the mean percentage of time that the intragastric pH was above 3, 4 and 5 between day 1 and day 5. However, neither the variation in pharmacokinetic parameters of ranitidine over the 5 days of treatment nor the subjects' H. pylori status could explain the decrease in the anti-secretory eect of ranitidine. 22 It seems that pharmacological tolerance develops even more quickly when H 2 RAs are administered intravenously rather than orally. In a study comparing the eects of intravenous ranitidine and omeprazole for treating patients with bleeding peptic ulcer, Labenz et al found a signi®cant loss of anti-secretory eect for ranitidine (0.25 mg/kg per hour after a bolus of 50 mg) during the second half of a 24 hour treatment when the intragastric pH was below 6 for 20±46% of the time compared with 0.1±0.15% with omeprazole (8 mg per hour after a bolus of 80 mg). 25 Furthermore, an individual dose titration of ranitidine has proved to be ineective in overcoming the loss of antisecretory eect once tolerance has been established. 24 The results of these studies may provide some explanation for the disappointing eect of H 2 RAs for adequately controlling gastric acid secretion, especially in conditions in which extended antisecretory treatment is needed.
Rebound acid hypersecretion
A temporary increase in gastric acid secretion to above pre-treatment values after the abrupt withdrawal of H 2 RAs has been reported in many studies in both healthy volunteers 27±29 and patients with a history of duodenal ulcer. 30, 31 This rebound acid hypersecretion may contribute to a rapid return of ulcer symptoms and ulcer recurrence. Interestingly, rebound is seen more often in subjects treated with cimetidine, ranitidine and nizatidine than in those receiving famotidine, although no direct comparison has been made between H 2 RAs. 28, 30 There is no dierence between H. pylori-positive and negative subjects with respect to the degree of rebound acid hypersecretion.
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The underlying mechanism of rebound acid hypersecretion is not clearly understood and cannot be associated with hypergastrinaemia. 28, 31 Recent animal studies have shown that upregulation of the H 2 -receptor and adenylate cyclase of the parietal cell may be the cause of acid hypersecretion after the withdrawal of prolonged treatment with H 2 RAs. 32 Although the rebound acid hypersecretion is a transient phenomenon, the clinical implications should not be ignored.
Low-dose H 2 RAs
Low-dose H 2 RAs such as ranitidine 75 mg or famotidine 10 mg have been available as over-the-counter medications for a few years and have proved to be eective and safe for self-controlling acid-related symptoms. 33, 34 Results from pharmacodynamic studies have shown that low-dose H 2 RAs are signi®cantly more eective for suppressing acid secretion than antacids and placebo even though the onset of action with the low-dose H 2 RAs is slower than that seen with antacids.
35±39
In a three-way cross-over study comparing the anti-secretory eects of single-dose ranitidine 75 mg with cimetidine 200 mg or placebo in 24 healthy volunteers, Grimley et al found that ranitidine was signi®cantly more eective than cimetidine or placebo for inhibiting intragastric acidity during both the daytime and the night-time periods. 35 The mean weighted intragastric acidity (mmol/l) in the daytime (0±10 hours postdosing) was 31.03 with placebo, decreasing to 10.37 (P 5 0.001 versus placebo) with ranitidine and 16.23 (P 5 0.001 versus placebo) with cimetidine. Ranitidine was signi®cantly more eective than cimetidine for controlling intragastric acidity during this period (P 5 0.001). During the night (10±20 hours post-dosing), similar dierences were observed, except for the comparison between cimetidine and placebo. The results suggest that the acid inhibitory eect achieved with ranitidine 75 mg lasts longer than that with cimetidine 100 mg. The anti-secretory eect of low-dose H 2 RAs can, however, be aected when the drugs are taken with food. 40 It is worth pointing out that most pharmacodynamic data published in the literature have been obtained from healthy volunteers. It is not clear, therefore, whether these data can be translated easily to patients who self-medicate to control acid-related symptoms. More studies are needed to assess the anti-secretory eect of low-dose H 2 RAs in the self-medicating population with acid-related symptoms.
PROTON PUMP INHIBITORS
The PPIs, omeprazole, lansoprazole, pantoprazole and rabeprazole are potent acidsuppressing agents that inhibit the ®nal common pathway for acid secretion by the parietal cell. They all contain a pyridylmethylsulphinyl benzimidazole moiety but dier from each other as a result of substitutions on the pyridine or benzimidazole rings. The PPIs are all weak bases with a pK a of about 4, and they share a generally similar mechanism of action at the parietal cell. As such, they concentrate in the acidic compartment of the secretory canaliculus of the parietal cells and then undergo an acid-catalysed transformation to a tetracyclic cationic sulphenamide. The sulphenamide reacts with speci®c cysteines, which results in the inhibition of the H , K -ATPase proton pumps. 41, 42 The binding is covalent with omeprazole, lansoprazole and pantoprazole, the inhibition of the activity of the acid pump being essentially irreversible, so the suppression of acid secretion is more complete than with other classes of anti-secretory drug. The substituted benzimidazoles, however, bind only to those pumps which are inserted into the secretory canalicular membrane and actively secreting acid, sparing those inactive pumps which are resting in the cytosol. 43 The inhibition of the secreting pumps results in an initially profound but timedependent elevation of intragastric pH. The recovery of acid secretion depends largely on the rate of de novo synthesis of acid pumps and the breakdown of the covalent complex. When the drug concentration, after the ®rst dose, has decreased to below threshold, any pumps that become inserted into the secretory canaliculus are able to secrete acid until the second dose. Newly active pumps are inhibited by the second dose, which also has a cumulative eect on the pre-existing pumps, although this cumulative inhibition of acid secretion will eventually be balanced out by newly synthesized pumps. Therefore, intragastric acidity is rapidly restored after a single oral dose of PPI.
Twenty-four hour gastric anacidity does not occur with the once or even twice-daily oral administration of PPIs. In order to achieve anacidity, the continuous intravenous administration of a PPI may be needed. The full restoration of acid secretion, as measured by 24 hour intragastric pH, generally occurs 72 hours after the last dose of a PPI. 43 Therefore, acid inhibition achieved by the PPIs targeting the proton pump is more eective than that achieved by agents targeting the parietal cell receptors.
PPIs have been shown in numerous clinical trials to be signi®cantly better than any H 2 RA for suppressing intragastric acidity. 2±5,19 PPIs result in a prolonged and highly eective inhibition of both basal and stimulated gastric acid secretion to all known stimuli, including meals. The eect of PPIs on intragastric acidity is highly dose dependent, the rapidity of onset of action depending on the bio-availability of the individual PPI.
44±46
The PPIs also have eect on peptic activity, decreasing pepsin output and reducing secretory volume, which directly inhibits peptic activity 47, 48 , whereas increasing the intragastric pH to a level greater than 4 indirectly eliminates peptic activity because the activation of pepsin is highly pH dependent. 17 This mechanism may partly explain the dierence between PPIs and H 2 RAs in healing peptic ulcer and especially erosive oesophagitis, because the intragastric pH achieved with H 2 RAs over a 24 hour period mostly still allows pepsin to show some proteolytic activity, leading to the retardation of mucosal healing.
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Omeprazole
Omeprazole was the ®rst of the PPIs shown to be superior to H 2 RAs in suppressing gastric acid secretion, relieving symptoms and healing gastric and duodenal ulcers and GORD.
2±5,49 Meta-analyses of clinical trials have shown a clear advantage for omeprazole over various dose regimens of H 2 RAs for the inhibition of 24 hour intragastric acidity and the healing of peptic ulcers and GORD. 2±5,19 Omeprazole 20 mg in the morning suppresses 90% of 24 hour intragastric acidity, 88% of nocturnal acidity and 92% of daytime acidity, whereas the best acid suppression pro®le achieved with H 2 RAs occurs with ranitidine 300 mg at bedtime, which inhibits 24 hour intragastric acidity by 68%, nocturnal acidity by 90% and daytime acidity by 50%.
2
Although the reduction of nocturnal intragastric acidity is an important determinant of ulcer healing, the suppression of 24 hour intragastric acidity has proved to be more critical, especially for the management of patients with GORD. If, for example, the suppression of nocturnal acidity is increased from 24 to 95% by an H 2 RA, a therapeutic gain of 21% in duodenal ulcer healing can be expected at 4 weeks. However, when the suppression of overall 24 hour acidity is increased from 40 to 100% by the inclusion of the PPI eect, the therapeutic gain is almost doubled, to 40%.
Omeprazole inhibits basal and maximum acid secretion stimulated by all known stimuli and in a dose-dependent manner, although there are marked variations in individual responses to omeprazole at lower doses of 5±10 mg. 50, 51 In an early report, Howden et al studied the eects of single and repeated doses of omeprazole 10 mg on gastric acid secretion in six healthy volunteers. 50 Analyses of gastric acid secretion were performed on the ®rst and seventh days of treatment, the results being compared with those obtained from a previous placebo study. After single doses of omeprazole, no signi®cant changes in basal acid output (BAO) or pentagastrinstimulated peak acid output (PAO) were seen compared with the results achieved with placebo. After 7 days treatment, however, there was a signi®cant reduction in both BAO (93.1%) and PAO (66.5%). Pharmacokinetic studies con®rmed a signi®cant increase in the bio-availability of omeprazole after repeated dosing since the C max increased signi®cantly in all subjects from 92 mg/l per hour on the ®rst day to 193 mg/l per hour on the seventh day and so did the area under the plasma omeprazole concentration time curve from 218 mg/l per hour to 339 mg/l per hour. 50 Higher doses of omeprazole (20±80 mg daily) provide a much more predictable inhibition of 24 hour intragastric acidity. Omeprazole 40 mg given in the morning and in the evening increased the median 24 hour intragastric pH to 5.0 and 4.5, compared with 1.9 with placebo, after 5 days of treatment in eight healthy volunteers in a crossover study. This is equivalent to an inhibition of hydrogen ion activity of over 99% for both omeprazole regimens. 52 The increase in the anti-secretory eect of omeprazole was caused by the increased absorption of the drug as measured by the C max and area under the curve (AUC). 52 This enhanced drug absorption may, in part, result from the pharmacological characteristics of omeprazole as an acid-labile compound such that its absorption increases as intragastric acidity decreases. Indeed, as reported in many other studies, the bio-availability of omeprazole increases with the duration of treatment. In healthy volunteers, the bio-availability of enteric-coated omeprazole 20 mg was 40% on the ®rst day, increasing to 65% on the seventh day of dosing. 53 Unlike the situation with H 2 RAs, the morning administration of omeprazole is better than evening dosing for suppressing 24 hour intragastric acidity. Chiverton et al found that, in patients with a healed duodenal ulcer, omeprazole 20 mg given in the morning was signi®cantly better than dosing in the evening for inhibiting gastric acid secretion. 54 The mean 24 hour intragastric pH was 3.9 + 1.8 for dosing in the morning, 2.9 + 1.1 for the evening dose and 1.7 + 0.1 for placebo (P 5 0.01 between the morning dose and placebo). 54 The profound suppression of 24 hour intragastric acidity also has an important impact on peptic activity. By plotting the frequency distribution of 24 hour intragastric pH against the peptic activity curve, Hirschowitz et al demonstrated that the majority of pH values achieved during treatment with cimetidine 1 g and ranitidine 300 mg daily were below 3 and within the range of maximum peptic activity, whereas omeprazole 30 mg daily consistently increased the intragastric pH to above 4, a level at which peptic activity is essentially abolished. 17 This additional advantage of omeprazole over H 2 RAs may be particularly relevant to healing both peptic ulcers and especially erosive oesophagitis.
Lansoprazole
Lansoprazole was the second PPI approved for treating patients with acid-related disorders. In approved therapeutic doses, lansoprazole, given orally, has a higher bioavailability and faster onset of anti-secretory eect than omeprazole, although both agents have many similarities in structure and mechanism of action. 53, 55 Results from pharmacokinetic studies have shown that, after a single dose of lansoprazole, the absolute bio-availability is 81% for the 15 mg and 85±91% for the 30 mg doses respectively 56, 57 and remains steady after repeated dosing. 56 The fast onset of action with lansoprazole has been con®rmed in a recent study in nine healthy volunteers, in whom once-daily lansoprazole 30 mg was given for 4 days, the maximum anti-secretory eect being obtained 6 hours after the ®rst dose and remaining consistent with subsequent dosing. 58 Pharmacodynamic studies have shown that lansoprazole inhibits basal and stimulated gastric acid secretion dose-dependently. 59, 60 In an early study of the eect of dierent doses of lansoprazole (15, 30 and 60 mg given for 1 week) on BAO and gastrinstimulated maximum acid output (MAO), MuÈ ller et al found a signi®cant and dosedependent decrease in BAO and MAO in all subjects. 61 On days 2 and 8, a signi®cant decrease in MAO was seen with all three doses of lansoprazole, the reduction in MAO observed on day 8 being more pronounced compared with the pre-treatment MAO (a fall of 94% for the 60 mg, 90% for the 30 mg and 69% for the 15 mg dose of lansoprazole respectively). Together with the decrease in MAO, the volume of gastric secretion was also signi®cantly reduced. All these changes returned to normal 1 week after stopping the treatment, suggesting the end of inhibition of acid secretion by lansoprazole. 61 In patients with healed duodenal ulcer and acid hypersecretion, lansoprazole also inhibited dose-dependently and signi®cantly the BAO and pentagastrin-stimulated PAO. 62 All three doses of lansoprazole (10, 20 and 30 mg administered as a single dose in the evening) signi®cantly inhibited the PAO after the ®rst dose on day 1 and repeated doses on day 7. It seems, however, that lansoprazole at a dose of 10 mg did not suciently inhibit the BAO even after repeated dosing for 7 days, whereas the BAO was eectively suppressed by doses of 20 and 30 mg but only on day 7. 62 The less eective anti-secretory eect reported in this study might have resulted from the dierent dosing schedule used in this study because the rate of absorption and bioavailability of lansoprazole have been shown to be lower when the dose is administered in the evening than with dosing in the morning. 56 Lansoprazole 30 mg given twice daily has proved to be the maximum dose frequency to achieve the optimal anti-secretory eect compared with other dose frequencies. 60, 63 Doses greater than 30 mg twice daily generally do not show any signi®cant advantages over lansoprazole 30 mg twice daily in suppressing intragastric acidity. 63 In a comparative study of multiple doses of lansoprazole (30 mg once daily, 30 mg twice daily, 45 mg twice daily and 60 mg twice a day) and omeprazole 20 mg twice a day, Timmer et al have shown that lansoprazole 30 mg twice daily has the best anti-secretory pro®le in terms of the holding time that the intragastric pH was above 5 64 , which has been suggested as an optimal intragastric pH for combination with antibiotics in the eradication of H. pylori infection. 43 Several comparative studies have indicated that a single dose of lansoprazole 30 mg has a better eect than omeprazole 20 mg in suppressing intragastric acidity 65±69 because of the pharmacokinetic dierences between the two PPIs. After the ®rst dose, the bio-availability of lansoprazole is over 85% and remains constant after repeated dosing 58, 66 , whereas the bio-availability of omeprazole is only 35% after the ®rst dose and rises to about 60% after repeated dosing. 50 The plasma half-life of lansoprazole is also longer and the t max signi®cantly shorter, hence lansoprazole 30 mg has a faster onset of action than omeprazole 20 mg, providing a maximum anti-secretory eect on day 1. 58, 66, 70 Results from a comparative study have shown that, when compared with placebo, lansoprazole 30 mg per day decreased meal-stimulated acid secretion over a 24-hour period on the ®rst day by 45.1%, followed by omeprazole 40 mg per day by 41.7%, lansoprazole 15 mg per day by 34.6%,and omeprazole 20 mg per day by 15.6%. 66 When compared with the new tablet formulation of omeprazole 20 mg, lansoprazole 30 mg has also been shown to be more eective for suppressing intragastric acidity, with a lower individual variability. 69 Therefore, according to pharmacodynamic studies, there is a dose-dependent eect for lansoprazole and omeprazole on the suppression of intragastric acidity with a potency order of lansoprazole 60 mg 4 lansoprazole 30 mg omeprazole 40 mg 4 omeprazole 20 mg lansoprazole 15 mg. 66, 67, 69, 70 The dierence in acid suppression between PPIs may be of clinical importance since the relief of acid-related symptoms as well as the healing of gastric and duodenal ulcers and erosive oesophagitis correlates with the degree of suppression of intragastric acidity.
2±5
Pantoprazole Like omeprazole and lansoprazole, pantoprazole binds covalently to the H , K -ATPase and irreversibly inhibits acid secretion by the proton pump. Although it shares many similarities in terms of structure and mechanism of action with the former two PPIs, pantoprazole is chemically more stable than omeprazole or lansoprazole under near-neutral conditions. 46 This greater acid stability may improve the tissue selectivity of the drug for the parietal cell since it reduces the likelihood of the compound reacting with proteins containing thiol groups that lie outside the parietal cell. After a single oral dose, pantoprazole 40 mg is absorbed rapidly, with an average t max of about 2.5 hours, this being slightly longer than the t max achieved with omeprazole (1±3 hours) and lansoprazole (2 hours). 71 The absolute bio-availability of pantoprazole has been reported to be 75±80% 71, 72 , this increasing with repeated dosing. Pantoprazole also shows dose linearity and thus a predictable anti-secretory eect. 73 Pantoprazole 20±60 mg once daily given orally produces a dose-dependent inhibition of 24-hour intragastric acidity in both healthy volunteers and patients with peptic ulcer disease 46, 74, 75 , with minimal additional anti-secretory eects at doses above 60 mg. 74, 76 Hannan et al 77 studied the anti-secretory eects of pantoprazole 40 mg and 60 mg given for 5 days and found that, on day 5, the median 24 hour intragastric pH values diered signi®cantly between placebo (pH 1.4), pantoprazole 40 mg (pH 2.3) and pantoprazole 60 mg (pH 3.5). The holding time for the intragastric pH above 3 was also signi®cantly longer with pantoprazole 40 mg (33%) and 60 mg (58%) compared with placebo (14.9%). This was equivalent to a decrease in 24 hour intragastric acidity of 87% with 40 mg and 99% with 60 mg pantoprazole respectively. 77 However, in a more recent study reported by Koop et al, pantoprazole 40, 80 and 120 mg was found to be equally eective for inhibiting gastric acid secretion. 76 In a review of the pantoprazole literature, Fitton and Wiseman found that the median 24 hour intragastric pH achieved with repeated dosing of pantoprazole 40 mg was 2.3±4.3, suggesting a considerable variation in the anti-secretory eect of pantoprazole after the oral administration of the 40 mg dose. 46 Like the former two PPIs, pantoprazole given in the morning is signi®cantly better than dosing in the evening. 78 This dierence is, however, caused largely by a greater suppression of daytime gastric acid secretion obtained with the morning dose than with dosing in the evening. 78 In comparison to H 2 RAs, pantoprazole 40 mg was signi®cantly superior to ranitidine 300 mg once daily in terms of the inhibition of median 24 hour intragastric pH (4.2 versus 2.7) and daytime pH (4.4 versus 2.0) in healthy volunteers. 46 In patients with grade II±III oesophagitis, pantoprazole 40 mg was signi®cantly more eective than ranitidine 150 mg twice daily for increasing the median intragastric pH and maintaining a longer holding time with the intragastric pH above 4, although there was no signi®cant dierence in the healing of the oesophagitis, probably because of the small number of patients studied. 79 When compared with omeprazole 20 mg and lansoprazole 30 mg, pantoprazole 40 mg was as eective or better than omeprazole 20 mg for suppressing gastric acid secretion, but no better than lansoprazole 30 mg on the ®rst day of dosing as a result of its relatively slower onset of action. 53, 80 Rabeprazole Rabeprazole is the fourth PPI that has been approved for treating acid-related disorders. Although rabeprazole was designed to be more potent than omeprazole in suppressing gastric acid secretion, it appears to dissociate more quickly and completely from the H , K -ATPase than does omeprazole or lansoprazole, suggesting a partially reversible inhibition of the proton pump. 81 In animal studies in vitro, rabeprazole was more potent than omeprazole for inhibiting the proton pump, but the duration of inhibition was considerably shorter than that seen with omeprazole 82 and lansoprazole because of the rapid dissociation from the proton pump. 83 In healthy volunteers, after single oral doses of rabeprazole of 1±80 mg, the maximum plasma concentration and AUC values increased with increasing doses, but the t max and plasma half-life were not dose dependent. 84 After a single dose of rabeprazole 20 mg, the C max was 0.406 mg/l, the t max 3.1 hours, the AUC 0.809 mg/l and the plasma half-life 1.02 hours in healthy volunteers. 84 The anti-secretory eect of rabeprazole has been examined in several randomized, placebo-controlled, cross-over studies.
85±87 In a 7 day study of the eect of dierent doses of rabeprazole on 24 hour intragastric acidity, Blanshard et al found that, on day 7, dosing with rabeprazole 10, 20 and 40 mg signi®cantly decreased the 24-hour intragastric acidity when compared with placebo. No signi®cant dierence in acid suppression was shown between the three doses of rabeprazole. 85 In another dose-ranging study involving 38 H. pylori-infected asymptomatic volunteers, rabeprazole at a dose of 5, 10, 20 or 40 mg once daily, or placebo, was given orally for 7 days. 86 The 24 hour intragastric acidity was monitored, as was the peptone meal-stimulated acid output. The authors found that the BAO and the mealstimulated acid output were signi®cantly and dose-dependently suppressed by rabeprazole compared with placebo on days 1 and 7, the inhibition being most pronounced on day 7. They also found that the half-time for the recovery of acid secretion was about 48 hours with the 5 mg dose and longer for the higher doses of rabeprazole. 86 In patients with re¯ux oesophagitis, rabeprazole has been shown to be eective for normalizing acid re¯ux time over the 24 hours that the oseophageal pH was below 4, with an increasing eect over the duration of treatment. 88 The 24 hour intragastric pH increased with rabeprazole 20 mg from 1.86 at base line to 3.71 on day 1 and 4.17 on day 7. With rabeprazole 40 mg, the intragastric pH increased from 2.01 to 4.37 on day 1 and 4.65 on day 7. 88 There is currently only one published study comparing the antisecretory eect of rabeprazole against that of omeprazole and placebo in healthy volunteers. 89 The results show that rabeprazole 20 mg given orally in the morning has a faster onset of anti-secretory activity than omeprazole 20 mg and produces a signi®cantly greater decrease in 24 hour intragastric acidity after a single dose of medication (406 mmol/l per hour on day 1 with rabeprazole versus 660 mmol/l per hour with omeprazole, P 5 0.001). 89 Esomeprazole Esomeprazole, the ®rst optical isomer of omeprazole, has recently been approved in Europe for treating acid-related disorders. Preliminary results suggest that esomeprazole 20 or 40 mg per day achieves a signi®cantly higher healing rate of erosive oesophagitis and provides faster symptom relief in patients with GORD than does omeprazole 20 mg per day.
90
Although esomeprazole was designed dierently from the existing PPIs and has a dierent pharmacokinetic pro®le, it, like omeprazole, acts by inhibiting the H , K -ATPase, the ®nal pathway of gastric acid secretion by the parietal cell. Preliminary results from several pharmacodynamic studies have shown that, on a dose-by-dose basis, the oral administration of esomeprazole is signi®cantly more eective than that of omeprazole, lansoprazole and pantoprazole for controlling intragastric acidity in patients with GORD. 91±93 Lind et al reported a cross-over study comparing the anti-secretory eects of esomeprazole 20 mg and 40 mg with omeprazole 20 mg once daily given for 5 days in 36 patients with GORD. 94 Esomeprazole 20 mg and 40 mg eectively maintained the intragastric pH at above 4 for a mean of 12.7 and 16.8 hours over the 24 hour period respectively, compared with 10.5 hours with omeprazole 20 mg. The median 24 hour intragastric pH achieved with esomeprazole 20 mg (pH 4.1) and 40 mg (pH 4.9) were also signi®cantly higher than that seen with omeprazole 20 mg (pH 3.6). Furthermore, the inter-patient variability in intragastric pH and AUC was consistently less with esomeprazole than with omeprazole. The signi®cantly improved pharmacodynamics of esomeprazole over the existing PPIs oers great potential for the better management of acid-related disorders, although more studies are needed to assess the eect of esomeprazole in dierent patient populations, its cost-eectiveness and its longterm safety.
SUMMARY AND CONCLUSION
Although eradicating H. pylori infection heals the majority of peptic ulcers, the pharmacological reduction of gastric acid secretion plays an important role in the management of acid-related disorders including ulcers associated with H. pylori infection and NSAID use, or non-H. pylori, non-NSAID ulcers or GORD. There is a dynamic relationship between the suppression of intragastric acidity and the healing of peptic ulcers and erosive oesophagitis. However, the suppression of intragastric acidity achieved with H 2 RAs has proved to be suboptimal for eectively controlling acidrelated disorders. Furthermore, the rapid development of tolerance to H 2 RAs and the rebound acid hypersecretion seen following the withdrawal of an H 2 RA further limit their clinical application.
PPIs eectively inhibit gastric acid secretion stimulated by all known stimuli and are more potent anti-secretory agents than H 2 RAs, as shown by numerous comparative, controlled clinical trials. Four PPIs are currently available, all of which have been proved to be very eective for suppressing intragastric acidity, even though variations exist in their rapidity of onset of action and the potency of acid inhibition after oral administration at the approved therapeutic doses, which may have important clinical implications for the treatment of GORD. Once-daily dosing in the morning is more eective than dosing in the evening for all PPIs with respect to the suppression of intragastric acidity and daytime gastric acid secretion in particular, which may be due to a better bio-availability achieved with morning dosing. When higher doses are needed, these drugs must be given twice daily to achieve an optimal suppression of 24 hour intragastric acidity.
Esomeprazole is a new PPI with an improved pharmacodynamic pro®le over the existing PPIs. Preliminary results from comparative trials have shown its clear superiority over the existing PPIs in suppressing intragastric acidity and healing
Practice points
. gastric acid suppression achieved with H 2 RAs is suboptimal for managing acidrelated disorders, especially GORD . an evening dose of H 2 RAs is more eective than a daily dose for controlling nocturnal acid secretion . a rapid development of tolerance to H 2 RAs occurs and cannot be overcome by dose adjustment . rebound acid hypersecretion is common with all H 2 RAs after stopping medication . low-dose H 2 RAs are signi®cantly more eective than placebo and antacids for controlling intragastric acidity . PPIs are signi®cantly more eective than H 2 RAs for suppressing gastric acid secretion . the healing of peptic ulcer and GORD and the relief of acid-related symptoms are signi®cantly correlated to the degree and duration of acid suppression over the 24 hour period and the length of anti-secretory treatment in weeks . dierences in bio-availability and pharmacodynamics exist between the PPIs at the recommended doses, and these may have clinical implications . on a dose-by-dose basis, esomeprazole is signi®cantly more eective than the existing PPIs for inhibiting intragastric acidity . PPIs are signi®cantly more eective given in the morning than in the evening for suppressing 24 hour intragastric acidity . twice-daily dosing is recommended if a high-dose PPI is required
Research agenda
. the anti-secretory eects of low-dose H 2 RAs need to be evaluated in selfmedicating populations . whether tolerance and rebound acid hypersecretion develop with low-dose H 2 RAs needs to be addressed . an updated analysis of the relationship between the suppression of intragastric acidity and the healing of GORD is needed, involving all the PPIs . pharmacological and pharmacodynamic studies are needed to evaluate the antisecretory eect of PPIs in non-H. pylori-non-NSAID-associated peptic ulcer disease because this type of peptic ulcer appears to be more common than was previously thought . the ecacy, cost-eectiveness and long-term safety of esomeprazole need to be evaluated in dierent patient populations and compared with those of the existing PPIs GORD. More studies are, however, needed to assess its ecacy in dierent patient populations, its cost-eectiveness and, in particular, its long-term safety in comparison with the existing PPIs.
